Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-06-03 Earnings Release
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Communiqué de presse : ASCO : de nouvelles données sur le Sarclisa appuient l’administration sous-cutanée avec un injecteur sur le corps
Earnings Release Classification · 99% confidence The document is a press release ("Communiqué de presse") announcing the presentation of new clinical data for the drug Sarclisa at the ASCO annual congress. It details the results of Phase III (IRAKLIA) and Phase II (IZALCO) studies regarding a new subcutaneous administration method using an on-body injector (OBI). The text focuses on scientific results, efficacy, safety profiles, and patient satisfaction, which are typical components of an Investor Presentation (IP) or a detailed scientific update. Since it is a press release announcing scientific findings presented at a major conference, and it contains detailed clinical data summaries, it aligns best with the Investor Presentation (IP) category, which covers detailed presentations on financials, strategy, and market position, often including clinical trial updates presented to investors/analysts. It is not a formal regulatory filing like a 10-K, nor is it just a brief announcement of a report (RPA/RNS). Q2 2025
2025-06-03 French
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
Regulatory Filings Classification · 98% confidence The document is explicitly titled "Press Release" and announces new clinical data for the drug Sarclisa presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. It details the results of the IRAKLIA phase 3 study and the IZALCO phase 2 study, focusing on efficacy, safety, and patient preference for a new subcutaneous administration method via an on-body injector. This type of announcement, which summarizes key findings from clinical trials and scientific presentations, is characteristic of an Earnings Release (ER) or a general press release announcing scientific progress. Since it is a detailed announcement of results rather than a full regulatory filing (like 10-K or IR) or a transcript of a call, the most appropriate classification among the provided options is 'ER' (Earnings Release), as these releases often include significant operational or clinical milestones that impact investor perception, even if they aren't strictly quarterly financial results. Given the context of presenting clinical trial data, it functions as a major corporate update. However, looking closely at the definitions, 'ER' is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is purely clinical/scientific data presentation, not financial results highlights. None of the other codes fit perfectly (it's not a 10-K, AR, CT, or IP). Since it is a press release announcing scientific data that will form the basis of regulatory submissions, it is a significant corporate announcement. In many databases, such scientific press releases are often categorized under a general regulatory/news category if a specific 'Clinical Data Release' category is missing. 'RNS' (Regulatory Filings / General regulatory announcements and fallback category) is the best fit as a fallback for a significant, non-financial, non-meeting-related corporate announcement that doesn't fit the other specific categories like LTR or MANG.
2025-06-03 English
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de la drépanocytose
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific regulatory event: the FDA granting Orphan Drug Designation to Rilzabrutinib for Sickle Cell Disease. It contains quotes from management, details about the drug's status in other regions (EU, China), and standard boilerplate sections about the drug, the disease, and the company (Sanofi), concluding with contact information and forward-looking statements. This format is characteristic of an official press release announcing a significant corporate or regulatory development, but it is not a comprehensive financial report (like 10-K or IR) or a transcript (CT). Since it is a formal announcement of a regulatory/development milestone, it fits best under the general category for regulatory announcements that aren't specifically financial results or shareholder actions. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing a regulatory designation, as it is not an Earnings Release (ER), a Capital Update (CAP), or a specific legal report (LTR). However, since the core content is a regulatory update about a drug designation, and it is a press release, RNS is the best fit among the provided codes for non-financial, non-meeting related announcements.
2025-06-03 French
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Press Release' and announces a specific regulatory event: the US FDA granting 'orphan drug designation' for the drug rilzabrutinib for sickle cell disease. This type of announcement, detailing regulatory milestones, clinical updates, and general company news outside of mandatory periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or press releases. Since there is no specific category for 'Press Release' that isn't a financial report, and it is a formal announcement of a regulatory action (Orphan Drug Designation), it is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to quarterly results, but here it is clearly a standalone news item about drug development. Given the options, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate fit for a non-financial, non-governance, non-legal-specific regulatory update like an Orphan Drug Designation announcement.
2025-06-03 English
SC TO-C Filing
Regulatory Filings
2025-06-03 English
6-K
Regulatory Filings
2025-06-02 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.